AbbVie Buys Apogee Therapeutics for $10.9 Billion for Experimental Eczema Drug
Pharmaceutical giant AbbVie announced it will acquire biotech company Apogee Therapeutics for $10.9 billion. Apogee is developing an experimental drug targeting atopic dermatitis, commonly known as eczema, which analysts consider highly promising. The deal is AbbVie's largest acquisition in more than five years.
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!